NON-ALCOHOLIC STEATOHEPATITIS
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise in cutting liver fat for NASH patients
Disease control CompletedThis study tested a daily pill called MGL-3196 in 125 adults with a serious liver disease called NASH (non-alcoholic steatohepatitis). The main goal was to see if the drug could reduce liver fat after 12 weeks compared to a placebo. The trial was completed and measured safety and…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Could a pill help reverse fatty liver damage?
Disease control CompletedThis early-stage study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking at whether the drug could improve fibrosis. Results are n…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
New drug for fatty liver disease passes first safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was not to treat any disease but to see if the drug is safe and how …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated May 01, 2026 15:58 UTC
-
Liver study tests drug safety in impaired patients
Knowledge-focused CompletedThis study looked at how the body processes efinopegdutide, a drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy volunteers. Researchers measured drug levels in the blood and checked for side effects after a single dose. The goal was …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC
-
First human test of new NASH drug begins in healthy women
Knowledge-focused CompletedThis early-phase study tested a single dose of the experimental drug J2H-1702 in 16 healthy women aged 19 to 45. The main goal was to check safety and how the drug moves through the body. This is a first step toward possibly treating non-alcoholic steatohepatitis (NASH), a seriou…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS
Phase: PHASE1 • Sponsor: J2H Biotech • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:01 UTC